Wells Fargo
GPCR icon

Wells Fargo’s Structure Therapeutics GPCR Stock Holding History

Wells Fargo’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Buy
7,818
+2,154
+38% +$147K ﹤0.01% 4307
2025
Q4 		$394K Sell
5,664
-394
-7% -$16.1K ﹤0.01% 4653
2025
Q3 		$170K Sell
6,058
-1,165
-16% -$23.2K ﹤0.01% 5020
2025
Q2 		$150K Sell
7,223
-122
-2% -$2.68K ﹤0.01% 4936
2025
Q1 		$127K Sell
7,345
-2,758
-27% -$67.6K ﹤0.01% 4972
2024
Q4 		$274K Buy
10,103
+6,763
+202% +$240K ﹤0.01% 4592
2024
Q3 		$147K Buy
3,340
+2,606
+355% +$101K ﹤0.01% 4778
2024
Q2 		$28.8K Buy
734
+288
+65% +$11.8K ﹤0.01% 5478
2024
Q1 		$19.1K Sell
446
-280
-39% -$11.8K ﹤0.01% 5590
2023
Q4 		$29.6K Buy
+726
New +$41.6K ﹤0.01% 5482

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wells Fargo's GPCR Position: Q1 2026 in Review

Wells Fargo increased its Structure Therapeutics (GPCR) stake by 38% in Q1 2026, buying an estimated $147K and bringing the position to 7,818 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #4307.

Wells Fargo first reported a position in GPCR in Q4 2023 and has held it in 10 quarters since. The position peaked at $394K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Wells Fargo held 7,818 shares of Structure Therapeutics worth $377K as of Q1 2026.
  • Wells Fargo bought 2,154 Structure Therapeutics shares in Q1 2026, an estimated $147K.
  • Structure Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4307 holding.
  • Wells Fargo first reported a position in Structure Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Wells Fargo's Structure Therapeutics position peaked at $394K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.